thalidomide has been researched along with Panuveitis in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Panuveitis: Inflammation in which both the anterior and posterior segments of the uvea are involved and a specific focus is not apparent. It is often severe and extensive and a serious threat to vision. Causes include systemic diseases such as tuberculosis, sarcoidosis, and syphilis, as well as malignancies. The intermediate segment of the eye is not involved.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although corticosteroids are usually the first-line therapy for non-infectious uveitis, their long-term use is limited by potentially serious side effects in all possible delivery routes." | 5.56 | Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG. ( Castro, BFM; Cenachi, SPF; Cotta, OAL; Fialho, SL; Guerra, MCA; Paiva, MRB; Silva, LM; Silva-Cunha, A; Vasconcelos-Santos, DV; Vieira, LC, 2020) |
| " Although corticosteroids are usually the first-line therapy for non-infectious uveitis, their long-term use is limited by potentially serious side effects in all possible delivery routes." | 1.56 | Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG. ( Castro, BFM; Cenachi, SPF; Cotta, OAL; Fialho, SL; Guerra, MCA; Paiva, MRB; Silva, LM; Silva-Cunha, A; Vasconcelos-Santos, DV; Vieira, LC, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castro, BFM | 1 |
| Vieira, LC | 1 |
| Vasconcelos-Santos, DV | 1 |
| Cenachi, SPF | 1 |
| Cotta, OAL | 1 |
| Guerra, MCA | 1 |
| Paiva, MRB | 1 |
| Silva, LM | 1 |
| Silva-Cunha, A | 1 |
| Fialho, SL | 1 |
1 other study available for thalidomide and Panuveitis
| Article | Year |
|---|---|
Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Humans; Intravitreal Injections; Models, Ani | 2020 |